Diabetic Neuropathy Market is Expected to Witness Significant Growth by 2036 Driven by Rising Diabetes Prevalence and Emerging Disease-Modifying Therapies | DelveInsight

The Diabetic Neuropathy Market is witnessing substantial growth driven by the increasing prevalence of diabetes mellitus, rising burden of diabetic complications, growing awareness of neuropathic disorders, and increasing demand for effective pain management therapies. Additionally, the anticipated launch of emerging therapies such as JOURNAVX/Suzetrigine, and other pipeline candidates is expected to reshape the Diabetic Neuropathy treatment landscape and accelerate market growth through 2036.
DelveInsight, a leading market research and consulting firm, announces the release of its latest report, "Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast-2036." The report provides an in-depth understanding of Diabetic Neuropathy, including historical and forecasted epidemiology, market trends, treatment landscape, emerging therapies, market size, market share, and industry outlook across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Key Takeaways from the Diabetic Neuropathy Market

*
The Diabetic Neuropathy market size across the 7MM is expected to grow significantly during the forecast period 2022-2036.

*
The United States accounted for the largest Diabetic Neuropathy market share among the 7MM and is expected to maintain its dominance throughout the forecast period.

*
The Diabetic Neuropathy market size in the United States was estimated at approximately USD 2.7 billion in 2025 and is projected to reach nearly USD 7.1 billion by 2036, reflecting substantial market expansion.

*
According to the International Diabetes Federation (IDF), more than 43 million adults in the United States are affected by diabetes, creating a substantial patient pool at risk of developing diabetic neuropathy.

*
Secondary epidemiological sources indicate that diabetic neuropathy affects more than 30% of individuals with diabetes in Japan, highlighting a considerable disease burden.

*
According to secondary research, approximately 32% of individuals with diabetes in Italy are affected by diabetic neuropathy.

*
DelveInsight estimates indicate that diagnosed prevalent cases of Diabetic Neuropathy continue to increase across the 7MM, driven by rising diabetes prevalence and aging populations.

*
In the United States, females account for approximately 60% of diagnosed diabetic neuropathy cases, while males represent approximately 40%.

*
Leading Diabetic Neuropathy companies such as Vertex Pharmaceuticals, Lexicon Pharmaceuticals, Grunenthal, Collegium Pharmaceuticals, and others are actively advancing novel therapies to improve patient outcomes.

*
Promising Diabetic Neuropathy drugs in development include Pilavapadin (LX9211) and JOURNAVX (Suzetrigine).

Keen to know more about the market? Request our sample page at Diabetic Neuropathy Market Report. https://www.delveinsight.com/sample-request/diabetic-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Diabetic Neuropathy Market

Rising Prevalence of Diabetes Mellitus

The increasing global prevalence of Type 1 and Type 2 diabetes continues to be the primary driver of the Diabetic Neuropathy market. As the diabetic patient population expands, the number of individuals developing diabetic neuropathy is expected to increase substantially, creating significant demand for effective treatments.

Growing Need for Effective Neuropathic Pain Management

Diabetic neuropathy is associated with chronic pain, sensory loss, motor dysfunction, and autonomic complications that significantly impact quality of life. Current treatment options focus primarily on symptom management, creating a strong demand for therapies that provide improved pain relief and functional benefits.

Emergence of Novel Disease-Modifying Therapies

Current approved therapies mainly address neuropathic pain without reversing underlying nerve damage. Emerging therapies targeting ion channels, neuroinflammation, nerve repair pathways, and neuronal protection are expected to transform the Diabetic Neuropathy drug market and address longstanding unmet clinical needs.

Increasing Healthcare Expenditure and Early Diagnosis

Growing healthcare investments, improved screening programs, and increasing awareness among healthcare professionals are supporting earlier diagnosis and treatment initiation, further contributing to Diabetic Neuropathy market growth.

Diabetic Neuropathy Competitive Landscape

The current Diabetic Neuropathy treatment market remains largely focused on symptomatic relief, as no approved therapies directly reverse nerve damage or halt disease progression. Existing treatment approaches primarily include glycemic control, pain management, physical therapy, and preventive care.

Among approved therapies, QUTENZA (capsaicin) from Grunenthal and NUCYNTA ER (tapentadol) from Collegium Pharmaceuticals represent key marketed products for neuropathic pain management associated with diabetic peripheral neuropathy.

The emerging Diabetic Neuropathy pipeline is led by innovative therapies such as Pilavapadin (LX9211) from Lexicon Pharmaceuticals and JOURNAVX (Suzetrigine) from Vertex Pharmaceuticals. These therapies target novel mechanisms including AAK1 inhibition and selective NaV1.8 inhibition, potentially offering differentiated efficacy and safety profiles compared to current treatment options.

Discover more about therapies set to grab major Diabetic Neuropathy market share @ Diabetic Neuropathy Treatment Landscape [https://www.delveinsight.com/sample-request/diabetic-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Recent Developments in the Diabetic Neuropathy Market

*
In November 2025, Lexicon Pharmaceuticals announced that it had scheduled an End-of-Phase II meeting with the US FDA and disclosed ongoing partnership discussions related to Pilavapadin.

*
According to presentations at the 44th Annual J.P. Morgan Healthcare Conference, Pilavapadin is expected to advance into Phase III clinical development.

*
In November 2024, Lexicon Pharmaceuticals completed enrollment in the Phase IIb PROGRESS trial evaluating Pilavapadin for diabetic peripheral neuropathic pain.

*
JOURNAVX (Suzetrigine) continues Phase III clinical development, with enrollment expected to be completed by the end of 2026.

*
Suzetrigine has received Breakthrough Therapy Designation (BTD) from the US FDA for the treatment of pain associated with diabetic peripheral neuropathy.

What is Diabetic Neuropathy?

Diabetic Neuropathy is a chronic and progressive complication of diabetes caused by prolonged hyperglycemia-induced nerve damage. The condition primarily affects peripheral nerves but may also involve autonomic and motor nerves. Symptoms commonly include numbness, tingling, burning sensations, stabbing pain, muscle weakness, balance impairment, and autonomic dysfunction such as orthostatic hypotension and gastroparesis. Diabetic Neuropathy significantly impacts quality of life and remains one of the most common long-term complications of diabetes.

Diabetic Neuropathy Epidemiology Segmentation

The Diabetic Neuropathy epidemiology section provides insights into historical and forecasted patient populations across the 7MM and includes:

*
Total Diagnosed Prevalent Cases of Diabetes Mellitus

*
Total Diagnosed Prevalent Cases of Diabetic Neuropathy

*
Gender-specific Diagnosed Prevalent Cases of Diabetic Neuropathy

*
Treated Cases of Diabetic Neuropathy

*
Country-specific Patient Population Analysis

Scope of the Diabetic Neuropathy Market Report

*
Therapeutic Assessment: Diabetic Neuropathy marketed and emerging therapies

*
Diabetic Neuropathy Market Dynamics: Key market drivers, barriers, opportunities, and future trends

*
Key Companies: Vertex Pharmaceuticals, Lexicon Pharmaceuticals, Grunenthal, Collegium Pharmaceuticals, and others

*
Key Therapies: JOURNAVX (Suzetrigine), Pilavapadin (LX9211), QUTENZA (Capsaicin), NUCYNTA ER (Tapentadol), and others

*
Competitive Intelligence Analysis: SWOT analysis and market entry strategies

*
Diabetic Neuropathy Market Size, Market Share, Treatment Trends, and Industry Outlook

*
Unmet Needs, KOL Views, Analyst Perspectives, Market Access, and Reimbursement Analysis

To know more about Diabetic Neuropathy companies working in the treatment market, visit @ Diabetic Neuropathy Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/diabetic-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]Table of Contents

*
Diabetic Neuropathy Market Report Introduction

*
Executive Summary for Diabetic Neuropathy

*
SWOT Analysis of Diabetic Neuropathy

*
Diabetic Neuropathy Patient Share (%) Overview at a Glance

*
Diabetic Neuropathy Market Overview at a Glance

*
Diabetic Neuropathy Disease Background and Overview

*
Diabetic Neuropathy Epidemiology and Patient Population

*
Country-Specific Patient Population of Diabetic Neuropathy

*
Diabetic Neuropathy Current Treatment and Medical Practices

*
Diabetic Neuropathy Unmet Needs

*
Diabetic Neuropathy Emerging Therapies

*
Diabetic Neuropathy Market Outlook

*
Country-Wise Diabetic Neuropathy Market Analysis (2022-2036)

*
Diabetic Neuropathy Market Access and Reimbursement

*
Diabetic Neuropathy Market Drivers

*
Diabetic Neuropathy Market Barriers

*
Diabetic Neuropathy Appendix

*
Diabetic Neuropathy Report Methodology

*
DelveInsight Capabilities

*
Disclaimer

*
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diabetic-neuropathy-market-is-expected-to-witness-significant-growth-by-2036-driven-by-rising-diabetes-prevalence-and-emerging-diseasemodifying-therapies-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.